Boehringer’s zongertinib receives Priority Review from U.S. FDA for the treatment of HER2 (ERBB2)-mutant advanced non-small cell lung cancer
Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...
Yahoo Finance6d
Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash
The Company had approximately $98.8 million in cash and cash equivalents as of December 31, 2024. Net cash used in operating activities was approximately $60.9 million, compared to $102.0 million ...